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Abstract 
This work examines the antitumor activity of an isomeric mixture (1), composed of 
the limonoids meliartenin and its interchangeable isomer 12-hydroxyamoorastatin. 
The results obtained showed that 1 displayed outstanding cytotoxic activity against 
CCRF-CEM, K562, A549 and HCT116 cells, with a highly selective effect on the 
latter, with an IC50 value of 0.2 µM. Based on this finding, HCT116 cells were 
selected to study the mechanism of action of 1. Cell cycle analysis revealed that 1 
induced sustained arrest in the S-phase, which was followed by the triggering of 
apoptotic cell death and reduced clonogenic capacity. This cytotoxicity was seen to 
be preceded by the upregulation of the tumor suppressor p53 and its target effector 
p21. In addition, it was found that p53 expression was required for efficient cell 
death induction, and thus that the toxicity of 1 relies mainly on p53-dependent 
mechanisms. Taken together, these findings position 1 as a potent antitumor agent, 
with potential for the development of novel chemotherapeutic drugs based on the 
induction of S-phase arrest. 
 
 
 
Keywords: meliartenin; 12-hydroxyamoorastatin; cytotoxicity; apoptosis; cell cycle 
arrest; HCT116; p53. 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
Abbreviations: ALL, acute lymphoblastic leukemia; BrdU, 5-bromo-2’-deoxyuridine; 
CML, chronic myeloid leukemia; DMSO, dimethyl sulfoxide; DOX, doxorubicin; FBS, 
fetal bovine serum; HU, hydroxyurea; MTT, 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide; PBS, Phosphate saline buffer; PBSTB, Phosphate saline 
buffer, tween and fetal bovine albumin; PCNA, proliferating cell nuclear antigen; PI, 
propidium iodide; pRB, retinoblastoma protein. 
 
 
Highlights 
 
• The isomeric mixture (1) is composed of meliartenin and its interchangeable 
isomer 12-hydroxyamoorastatin.  
• Compound 1 showed a strong cytotoxic effect against a panel of human tumor 
derived cell lines. 
• Compound 1 induced sustained S-phase cell cycle arrest. 
• Compound 1 induced apoptosis and decreased clonogenic potential. 
• Wild-type p53 expression was required for efficient cell death induction. 
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1. Introduction 
 
Cancer is the second leading cause of death worldwide. Approximately 14 
million new cases were reported in 2012 and 8.8 million deaths occurred in 2015 due 
to this disease (Ferlay et al., 2015). Factors such as high costs, side effects and the 
therapeutic limitations of conventional chemotherapeutic drugs mean that there is an 
urgent need to develop new active selective anticancer agents.  
The effectiveness and the diversity of structures of plant-derived metabolites 
are driving their resurgence as an important source of molecules for drug discovery 
(Balunas and Kinghorn, 2005; Kristanc and Kreft, 2016).  
Despite great advances in the field of plant-drug discovery, the plant world 
remains largely unexplored in some geographical areas, as in the case of flora from 
Argentina (Joray et al., 2015). The genus Melia is well-known as a rich and valuable 
source of bioactive tetranortriterpenoids known as limonoids (Zhao et al., 2010). These 
compounds are formed from the loss of the four terminal carbons of the side chain of 
the apo-tirucallol or apo-euphol skeleton, resulting in a β-substituted furanyl ring at C-
17 (Tan and Luo, 2011). In previous research conducted by our group, the fractionation 
of a kernel extract obtained from Melia azedarach L. led to the isolation of meliartenin, 
an antifeedant limonoid, which exists as a mixture with its tautomeric isomer 12-
hydroxyamoorastatin (Carpinella et al., 2002). The cytotoxicity of 12-
hydroxyamoorastatin, in terms of its half- inhibitory concentration (IC50) against a few 
tumor cell lines, has been previously reported (Ahn et al., 1993; Itokawa et al., 1995; 
Polonsky et al., 1979). However, despite its potential as an antitumor drug, the 
mechanistic details involved in its biological effect together with meliartenin, have not 
yet been explored. 
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Many proteins have been described as playing a dual role in cell cycle control 
and apoptosis (Foster, 2008). Among them, p53 is a ubiquitous transcription factor that 
has an essential role in protecting the cell from multiple stressors (Gottifredi et al., 
2001a). P53 exerts many of its functions as a transcriptional activator and repressor by 
regulating the expression of a number of genes that control cell cycle, cell death, and 
other cellular functions (Brown et al., 2009; Gottifredi et al., 2001b). The protein 
p21WAF1 (hereafter p21) is a key downstream effector of p53 which modulate 
cyclin/CDK activity, pRB degradation and PCNA inhibition, thus leading to the 
activation of the G1/S and S-phase checkpoints (Mirzayans et al., 2012).  
In this study, the antitumor activity of the interchangeable isomeric mixture 
(hereafter 1) of meliartenin and 12-hydroxyamoorastatin was evaluated over a panel of 
human tumor-derived cell lines, resulting in a cytotoxic effect that was highly selective 
of the human colorectal carcinoma cell line HCT116 over the rest of the assayed cell 
lines. Mechanistic analysis revealed that 1 induced cell cycle arrest and triggered 
apoptotic cell death at the same time as it decreased the clonogenic potential of the 
cells. It was also demonstrated that these effects were mediated by the upregulation of 
the expression of p53 and p21, and that wild-type p53 expression was required for cell 
death induction. In light of these findings, the present study sets the ground for the 
potential use of compound 1 for the development of novel anticancer drugs. 
 
2. Materials and methods 
 
2.1. Chemicals, equipment and reagents  
 
The isomeric mixture (1) of meliartenin and 12-hydroxyamoorastatin (Fig. 1) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
was isolated from Argentine M. azedarach fruits (Carpinella et al., 2002). 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), propidium iodide (PI), 
5-bromo-2’-deoxyuridine (BdrU), RNase A and hydroxyurea (HU) were purchased 
from Sigma-Aldrich CO (St Louis, MO). Doxorubicin hydrochloride 99.8% (DOX, 
Synbias Pharma Ltd.) was purchased from Nanox Release Technology (Buenos Aires, 
Argentina). SYTOX Red was obtained from Invitrogen Life Technologies (Carlsbad, 
CA) and Annexin V was purchased from BD Biosciences (San Jose, CA). Sterile plastic 
material was purchased from Greiner Bio-One (Frickenhausen, Germany). Flow 
cytometry analysis was performed in a Becton-Dickinson (BD) FACSCanto II (BD 
Biosciences, San Jose, CA) and in an Attune NxT (Invitrogen Life Technologies 
(Carlsbad, CA) flow cytometer. 
 
2.2. Cell lines and culture conditions 
 
 K562 chronic myeloid leukemia (CML) (Rumjanek et al., 2013) and CCRF-
CEM acute lymphoblastic leukemia (ALL) (Efferth et al., 2002) cells were a generous 
gift from Dr. V. Rumjanek (Institute of Medical Biochemistry Leopoldo de Meis, 
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil) and Dr. T. Efferth 
(Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, 
Germany), respectively. Human lung and colorectal cancer cells, A549 and HCT116 
respectively, were purchased from American Type Culture Collection (ATCC, 
Rockville, USA). Leukemic cells were grown in RPMI 1640 medium (Invitrogen Life 
Technologies, Carlsbad, CA) while the adherent cell lines were grown in DMEM 
(Invitrogen Life Technologies, Carlsbad, CA), both media supplemented with 10% 
heat-inactivated fetal bovine serum (FBS), 2 mM glutamine (Invitrogen Life 
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Technologies, Carlsbad, CA) and penicillin (100 units/mL)-streptomycin (100 µg/mL) 
(Invitrogen Life Technologies, Carlsbad, CA), at 37°C in a 5% CO2 humidified 
environment. Cells were sub-cultured twice a week and used when under 20th passage 
from frozen stocks. All experiments were performed with cells in the logarithmic 
growth phase with cell viabilities over 90%, determined by staining with trypan blue. 
Isogenic p53-/- and p21-/- cell lines were established by knocking out the p53 and p21 
genes by homologous recombination (Bunz et al., 1998; Waldman et al., 1995). 
 
2.3. Cell proliferation assay 
 
The MTT colorimetric assay was performed as previously described (Joray et 
al., 2015). Briefly, 2 x 104 adherent cells suspended in 100 µL of complete growth 
medium were seeded in 96-well plates. After 24 h, 100 µL of medium was added in the 
presence of serial two-fold dilutions of compound 1 (0.0003-37.5 µΜ) previously 
dissolved in acetonitrile (1% v/v since no adverse effects were observed at this 
concentration). In the case of leukemic cells, 5 x 104 cells suspended in 100 µL of 
growth medium were seeded in 96-well plates containing 100 µL of medium in the 
presence of serial two-fold dilutions of 1 previously dissolved in acetonitrile. 
After 72 h incubation, 20 µL of 5 mg/mL solution of MTT in sterile PBS was added to 
each well and further incubated for 4 h at 37°C. Then, the supernatants were removed 
and replaced with 100 µL DMSO to solubilize the resulting purple formazan crystals 
produced from metabolically viable cells. Absorbance was measured with an iMark 
micro-plate reader (Bio-Rad, USA) at 595 nm. The chemotherapeutic DOX dissolved in 
sterile water (0.001-34.5 µΜ) and 1% acetonitrile were used as positive and negative 
controls, respectively. The percentage of cytotoxic activity of the assayed compound 
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was determined by use of the following formula: Cytotoxicity (%) = [1- (Optical 
density of treated cells - Optical density DMSO) / (Optical density of control cells - 
Optical density DMSO)] x 100. 
 Half-inhibitory concentrations (IC50) represent the concentrations of the tested 
samples required to inhibit 50% cell proliferation (compared to the solvent control, 
which showed no differences in comparison to untreated control) and were calculated 
from the mean values of data from wells. 
 
2.4. Cell-cycle analysis 
 
 Changes in cell-cycle distribution were assessed by flow cytometry. HCT116 
cells in complete growth medium at a density of 2 x 105 cells/well were seeded in 12-
well plates (final volume 1 mL). After 24 h, the cells were treated with 1 (0.2 - 0.8 µM) 
for 24, 48 and 72 h. Cells treated with DOX 0.6 µM or HU 2 mM, both compounds 
dissolved in sterile water, were simultaneously run as positive controls. Control cells 
were devoid of 1, containing only 1% acetonitrile. After treatment, cells were collected 
and fixed in 70% ice-cold ethanol and kept at -20°C for at least 24 h. Before analysis, 
the cells were washed twice and suspended in a solution of PBS containing 50 µg/mL 
PI and 100 µg/mL RNase A and incubated for 30 min at room temperature in the dark. 
Cellular DNA content was analyzed by flow cytometry. The relative distribution of at 
least 10,000 cells was analyzed using FlowJo software version 7.6.2 (Tree Star, Inc. 
Ashland, OR).  
 
2.5. 5-bromo-2’-deoxyuridine incorporation assay  
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HCT116 cells in complete growth medium at a density of 5 x 105 cells/well were 
seeded in 6-well plates (final volume 2 mL). After a 24 h period, cells were treated with 
1 (0.2 - 0.8 µM) for 24, 48 and 72 h. Control cells were devoid of 1, containing only 1% 
acetonitrile. Cells treated with HU 2 mM dissolved in sterile water were simultaneously 
run. For detection of replicative DNA synthesis, 10 µM BrdU was added 20 min before 
collecting the cells. Cells were fixed in 70% ice-cold ethanol, permeabilized with 2N 
HCl and 0.5% TritonX-100 for 15 min at room temperature and neutralized with 
sodium borate 0.1 M (pH 8.5). After washing twice with PBSTB (PBS, Tween 0.2% 
and BSA 0.5%), cells were incubated with 100 µL of anti-BrdU antibody, clone BU-1 
from Millipore, for 1h at room temperature. Subsequently, cells were washed twice with 
PBSTB, spun down and incubated for 1 h with a FITC-conjugated secondary antibody 
from Jackson ImmunoResearch. After labeling, cells were washed as described above 
and re-suspended in PBS containing PI (50 µg/mL) and RNase A (100 µg/mL), and 
incubated for 30 min at room temperature in the dark. Samples were immediately 
analyzed by flow cytometry. The relative distribution of at least 10,000 cells was 
analyzed using FlowJo software version 7.6.2 (Tree Star, Inc. Ashland, OR).  
 
2.6. SYTOX Red dead cell stain 
 
HCT116 cells in complete growth medium were seeded at a density of 2 x 105 
cells/well in 12-well plates (final volume 1 mL). After 24 h, cells were treated with 1 
(0.2 - 0.8 µM), DOX 0.6 µM or HU 2 mM during 24, 48 and 72 h. Control cells 
containing 1% acetonitrile were simultaneously run. After treatment, cells were 
harvested and stained with 5 nM of SYTOX Red stain, following the manufacturer’s 
protocol. Samples were analyzed by flow cytometry. The relative distribution of at least 
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10,000 cells was analyzed using FlowJo software version 7.6.2 (Tree Star, Inc. Ashland, 
OR). 
 
2.7. Assessment of apoptosis by Annexin V/SYTOX Red double staining assay 
 
 HCT116 cells (2 x 105/well) cultured in complete growth medium were plated in 
12-well plates (final volume 1 mL) for 24 h and then treated with compound 1 0.2 µM, 
HU 2 mM or 1% acetonitrile for 24, 48 and 72 h. After incubation, cells were harvested, 
washed and suspended in cold PBS. The proportion of cells undergoing apoptosis was 
examined by a double staining experiment using a FITC labeled Annexin V and 
SYTOX Red, as instructed by the manufacturer´s protocol. At least 10,000 cells were 
analyzed and quadrant analysis was performed using FlowJo software version 7.6.2 
(Tree Star, Inc. Ashland, OR). Cells in early stages of apoptosis stained as Annexin 
V+/SYTOX Red -, whereas cells in late apoptosis stained as Annexin V+/SYTOX Red+. 
 
2.8. Colony formation assay 
 
HCT116 cells were seeded in 96-well plates at a density of 2 x 104 cells/well. 
After 24 h, cells were treated with 1 (0.02 µM – 0.4 µM) or 1% acetonitrile for 72 h. To 
evaluate the remnant ability of a single cell to grow into a colony after treatment, cells 
were harvested, counted and immediately re-plated in 6-well plates containing drug-free 
medium at different densities ranging from 80-2560 cells per well. After 10 days of 
incubation, colonies were washed with PBS, fixed and stained with a mixture of MeOH 
/ glacial acetic acid 75:25 containing 0.5% crystal violet for 30 min at room 
temperature. After staining, plates were carefully washed by immersion in tap water and 
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left to dry. Colonies were counted using ImageJ software. Plating efficiency (PE) of 
control cells was calculated as PE = (number of colonies formed/number of cells 
seeded). The percentage surviving fraction (SF%) after treatments was calculated in 
terms of PE as follows: SF = [number of colonies formed after treatment/(number of 
cells seeded x PE)] x 100.   
 
2.9. Western Blot 
 
HCT116 cells (5 x 105 cells/well) were seeded in 6-well plates containing 
complete growth medium, cultured for 24 h and then treated with 1 (0.2-0.8 µM), DOX 
0.6 µM, HU 2 mM or 1% acetonitrile during 24 and 48 h (final volume 2 mL). After 
treatment, samples were lysed directly in Laemmli buffer. Western blots were 
performed using anti-p21 antibody (C19- Santa Cruz, USA), polyclonal antibody 
against human p53 (1801- Santa Cruz, USA) and a polyclonal antibody against actin as 
a loading control (Sigma-Aldrich CO,St Louis, MO). Secondary antibodies coupled to 
infrared dyes were used for detection using an Odyssey® CLx Imaging System (LI-COR 
Corporate, USA). Data analysis and quantifications for each protein, correcting for 
loading, was performed using Image Studio software (LI-COR Corporate, USA).  
 
2.10. Effect on the isogenic cell lines HCT116 p53 -/- and HCT116 p21-/- 
 
To determine if the induction of p21 and p53 was actively implicated in the 
cytotoxicity induced by 1, the effect of this was evaluated in a co-culture of wild-type 
HCT116 and its isogenic derivatives HCT116 p53 -/- and HCT116 p21 -/- tagged with 
different fluorescent proteins. Briefly, three isogenic cell lines were cultured separately 
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and, 24 h prior to the addition of 1 (0.01 – 0.2 µM) or 1% acetonitrile, they were co-
plated in equal numbers in a multi-well plate. A mixture of isogenic cell lines (4,000 
cells per 96-well) was cultured for 6 days and the differential survival was assessed by 
analyzing the ratio of the different cell populations by FACS analysis. The similar 
proliferation index of each cell line without treatment was confirmed in the control 
group corresponding to each experiment.  
 
2.11. Statistical analysis  
 
The results are expressed as mean ± SE. Data were analyzed using two-way 
analysis of variance (ANOVA) using GraphPad Prism software (GraphPad Prism 5.0, 
GraphPad Software, Inc., CA, USA), with p -values ≤ 0.05 as statistically significant. 
All experiments were conducted in duplicate or triplicate at least three times in 
independent experiments. The 50% inhibitory concentrations (IC50) were calculated by 
log-probit analysis, responding to at least ten concentrations at the 95% confidence level 
with upper and lower confidence limits.  
 
3. Results  
 
3.1 Compound 1 exerted a potent and selective cytotoxic effect against HCT116 cells 
 
The anti-proliferative effect of 1 was evaluated by MTT assay against a panel of 
tumor-derived cell lines. Compound 1 showed a strong cytotoxic effect against all the 
cell lines evaluated, with IC50 values ranging from 0.2 to 4.6 µM (Table 1). The IC50 
values were in all cases below 10 M, the threshold established by the US National 
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Cancer Institute plant screening program for considering a pure compound as cytotoxic 
(Kuete et al., 2014). This activity was considerably stronger in HCT116 cells, with an 
IC50 value of 0.2 µM. The half-inhibitory effect of 1 was in a similar range to that found 
for DOX (IC50 = 0.1-5.1 µM), which was used as a positive control.   
Based on these findings, the HCT116 cell line was selected for subsequent 
studies to examine the molecular mechanisms underlying the antitumoral effect 
mediated by 1.  
 
3.2. Compound 1 induced S phase cell cycle arrest 
 
After treatment with cytotoxic agents, cells can enter into a death program or 
stop their cell cycle progression, which in turn can also trigger death by apoptosis if 
cells cannot overcome the damage (León et al., 2009). To assess the influence of 1 on 
the progression of HCT116 cells through the cell cycle, the DNA content after PI 
staining was analyzed. Intriguingly, treatment with 1 led to a time-dependent increase (b 
= 0.011; p = 0.0029; CI 95% = 0.004-0.017) in the number of cells transiting the S-
phase of the cell cycle (Fig. 2). After 24 h of treatment with 1, the cells began to 
accumulate in the S-phase (Fig. 2A and B). This effect became significant (p < 0.001) 
after 48 h, leading to percentages of S-phase cells up to 2 times higher than in control 
cells (Fig. 2B). This arrest remained even after 72 h of exposure to 1 at 0.4 and 0.8 µM 
(p < 0.001) (Fig. 2B). In addition to DOX, which is known to induce G2-M arrest 
(Rezaei et al., 2012), HU was introduced as a second positive control, since it is well-
established that it induces accumulation of S-phase cells by ribonucleotide deprivation 
(Gottifredi et al., 2001a). Remarkably, while HU triggered the accumulation of cells at 
the G1-S transition, 1 induced the accumulation of cells throughout S-phase (Fig. 2A). 
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No significant differences (p > 0.05) were observed between the absolute number of 
cells in S-phase between this positive control and compound 1 at 0.4 and 0.8 µM at 48 
and 72 h of treatment (Fig. 2B).  
To gain further insight in the type of S-phase arrest induced by 1, BrdU (5-
bromo-2’-deoxyuridine) incorporation experiments were performed. BrdU is a 
thymidine analogue that incorporates into newly synthesized DNA. This type of 
experiment enables cell cycle arrest to be determined and also whether the S/phase 
accumulation is linked to a delay in the progression through S-phase or to a permanent 
block within this phase (by the evaluation of the percentage of cells actively 
synthesizing DNA, BrdU+ vs BrdU-). In agreement with the results obtained when 
analyzing DNA content after PI staining alone (Fig. 2A), a strong arrest was observed at 
the G1/S transition after HU treatment and a widespread arrest after treatment with 1 in 
S-phase at 48 and 72 h (Fig. 3A). Subsequently, the percentage of BrdU+ vs BrdU- 
within S-phase at different time points after treatment was quantified. While at 24 h the 
results were consistent with a delay in S-phase progression, at 48 and mainly at 72 h it 
became evident that a sub-population of cells treated with 1 were no longer 
incorporating BrdU (Fig. 3B), and therefore could be considered as permanently 
arrested.  
 
3.3. Compound 1 triggered cell death in a time-dependent manner 
 
  Since it is well-established that a permanent arrest in S-phase is an event that 
would eventually lead to cell death (Gottifredi and Prives, 2005), we decided to further 
explore this effect with 1. In fact, the experiments of PI incorporation (Fig. 2A) showed 
that the accumulation of cells in S-phase was accompanied by an increase in the hypo-
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diploid (sub-G1) population after 48 h of treatment with 1, suggesting the concomitant 
induction of cell death. To confirm this, cell death induction was assessed by flow 
cytometry using SYTOX Red stain. It was observed that 1 induced cell death in 
HCT116 cells in a time-dependent manner (b = - 0.825; p = < 0.0001; CI 95% = -0.984 
to -0.666) (Fig. 4A). While the percentage of viable cells in DOX treatment differed 
with respect to control only at 72 h (p < 0.001), HU showed significant differences (p < 
0.001) from 48 h and the treatments with 1 showed significant differences (p < 0.001) at 
all assayed times from 0.2 µM (Fig. 4A). On the other hand, after 72 h, treatment with 1 
at 0.2, 0.4 and 0.8 µM showed a 53%, 64% and 66% death, respectively (Fig. 4B).  
 
3.4. Compound 1 led to apoptotic cell death and reduced the proliferative potential of 
HCT116 cells 
 
  The experiments using SYTOX Red stain enabled confirmation of the induction 
of cell death when 1 was applied at the dose of 0.2 µM. Since many anticancer drugs, 
including those from natural origin, exert their effect through different mechanisms that 
ultimately trigger apoptotic cell death (Pieme et al., 2014), we examined whether the 
cell death observed was in fact apoptosis. After treatment, HCT116 cells were double-
stained using Annexin V-FITC and SYTOX Red to discriminate between apoptosis and 
other types of death such as necrosis (Liao and Lieu, 2005). Data analysis showed an 
increase in the proportion of cells undergoing apoptosis, with 74.3% of early and late 
apoptotic cells after 72 h exposure to 1 (Fig. 5). It is worth noting that a small 
percentage of necrotic cells (SYTOX Red + / Annexin V-FITC -) were observed at 24 h 
of treatment with 1, which suggests that apoptosis may be the main, but not the only 
mechanism involved (Fig. 5). 
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Another important question for exploring the potential of compound 1 as a 
potent antitumoral agent was the proliferative capacity of the small percentage of cells 
that survive the treatment. To evaluate this, a clonogenic assay was carried out (Franken 
et al., 2006). After being submitted to different concentrations of 1 for 72 h of 
treatment, HCT116 cells were re-plated at a very low density in drug-free growth 
medium to evaluate the remnant capacity of individual cells to generate colonies. We 
found that 1 remarkably reduced the clonogenic capacity of HCT116 cells, with a mean 
survival fraction of 0.04 µM (Fig. 6A), which is five times lower than the IC50 
determined by the MTT assay (0.2 µM). 
 
3.5. The antitumoral activity of 1 was dependent on p53  
 
As previously stated, compound 1 induced S-phase cell cycle arrest and 
apoptosis in HCT116 cells. Considering the key role of p53 and p21 in the cellular 
response against genotoxic agents (Gottifredi et al., 2001a; Mansilla et al., 2013), the 
goal of this study was to evaluate the effect of 1 on the expression of both proteins. It 
was found that treatment with 1 (0.2-0.8 µM) increased the expression of p53 and p21 
proteins in a time- and dose-dependent manner (Fig. 7A). The expression profile of 
these proteins was similar to the treatment with HU but not to that with DOX (Fig. 7A).  
To determine if the induction of p21 and p53 is actively implicated in the 
cytotoxicity induced by 1, an assay was performed to assess in parallel the cell survival 
in a co-culture condition of HCT116 wild-type cells with two isogenic derivatives 
(HCT116 p53-/- and p21-/-). In this assay, each cell line was recognized by the stable 
expression of fluorescent proteins. When the effect of 1 was evaluated using this assay, 
an outstanding differential sensitivity was found of p53-/- cells in comparison to p21-/- 
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and wild-type cells (Fig. 7B). Indeed, at 0.2 µM, more than 80% of the viable cells 
corresponded to p53-/-. We concluded that the expression of p53 (but not of p21) is 
critical for the cytotoxicity exerted by 1. 
 
4. Discussion 
 
The fact that cancer still has high mortality rates encourages researchers to find 
novel candidate compounds for therapies. With this in mind, the cytotoxic effect of an 
isomeric mixture (1) formed by two interchangeable tetranortriterpenoids, meliartenin 
and 12-hydroxyamoorastatin (Fig. 1) (Carpinella et al., 2002), was evaluated against a 
panel of tumor cell lines. As observed in Table 1, compound 1 showed a strong 
cytotoxic activity (0.2 - 4.6 µM) on CCRF-CEM, K562, A549 and HCT116 cells. 
Comparing the inhibitory values among the assayed cell lines, it was noteworthy that 1 
exerted a highly specific toxic effect against HCT116. This was evident from the IC50 
ratios calculated. In fact, when the IC50 values of 1 against CCRF-CEM (IC50 = 1.4 
µM), K562 (IC50 = 4.6 µM) and A549 (IC50 = 4.3 µM) were compared to those of 
HCT116 cells (IC50 = 0.2 µM), ratios of 7, 23 and 22 were observed, respectively. 
Taking into account previous classifications, IC50 ratios higher than 6 are rated as highly 
selective (Acton et al., 1994). In contrast, this specificity with respect to all the assayed 
cells was not observed with the commercial chemotherapeutic agent DOX, which was 
used as a positive control (Table 1).  
Our first intriguing finding was that treatment with 1 induced a time-dependent 
increase in the number of cells transiting the S-phase of the cell cycle, with a similar 
activity from 0.4 µM to that obtained with HU at 48 and 72 h (Fig. 2B). Subsequent 
detection with an anti-BrdU antibody confirmed a sustained anti-proliferative effect of 1 
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on HCT116 cells (Fig. 3A and B). This is remarkable considering that compounds 
shown to induce arrest at the S-phase are quite rare (Hu et al., 2007). S-phase-arresting 
natural products, many of them derived from plants, have been evaluated for their 
potential clinical utility. Among these, β-lapachone, an ortho naphthoquinone originally 
isolated from the tree Tabebuia avellanedae (commonly known as Lapacho) (Pardee et 
al., 2002), is currently undergoing Phase I clinical trials against solid tumors 
(Cheriyamundath et al., 2017). Interest in such compounds relies on the fact that DNA 
replication is a critical process that can be delayed, but cannot be indefinably arrested 
(Gottifredi and Prives, 2005), thus turning S-phase into a “strategic” stage for targeting 
tumor cells. A good example is the case of HU, a S-phase arresting agent that has had 
great success in the treatment of several types of blood cancers (Leitch et al., 2016). Our 
data demonstrated that, similar to HU, the stronger induction of cell death correlates 
with the time points at which the arrest of S-phase becomes permanent (Fig. 3B and 
Fig. 5).  
In addition to slowing down the cellular progression through S-phase, flow 
cytometry analysis after SYTOX Red stain showed that 1 induced cell death in a time-
dependent manner (Fig. 4A), reaching percentages of death higher than 53% from 0.2 
µM at 72 h (Fig. 4B). These results indicated that cells could not overcome the S-phase 
arrest induced by this compound, leading to cell death. Moreover, this percentage of cell 
death observed after 72 h of treatment with 1 at 0.2 µM was consistent with the IC50 
determined by MTT (IC50 = 0.2 µM, Table 1), indicating that the anti-proliferative 
effect observed after treatment with 1 is a consequence of cell death rather than of a 
permanent arrest of the cell cycle.  
Furthermore, Annexin V/SYTOX Red double staining demonstrated that 1 was 
able to induce apoptosis in HCT116 cells (Fig. 5) with values higher than 70% at 72 h. 
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Thus, our results suggest that 1 triggers apoptosis due to a sustained blockage of S-
phase progression.  
It was also found that 1 was not only capable of killing HCT116 but also 
strongly impaired its clonogenic potential at a concentration as low as 0.04 µM (Fig. 6), 
which reinforces its potential as an effective antitumor agent. This is a very important 
finding, since drugs that suppress clonogenicity hold potential to treat a variety of 
tumors by inhibiting their ability to expand and colonize (Cheriyamundath et al., 2017). 
Few studies have been reported regarding the mechanism of cytotoxicity exerted 
by limonoids isolated from M. azedarach. 12-O-acetylazedarachin B (Zhou et al., 
2016), toosendanin, meliarachin C and 3-O-deacetyl-4’-demethyl-28-oxosalaninin 
(Akihisa et al., 2013) were found to exert antiproliferative and apoptotic effects on HL-
60 cells (Akihisa et al., 2013; Ju et al., 2013; Zhou et al., 2016). Particularly, 12-O-
acetylazedarachin B, meliarachin C and toosendanin, all of them trichilin-type 
limonoids like meliartenin and 12-hydroxyamoorastatin, presented lower IC50 values 
(0.016, 0.65 and 0.005 µM, respectively by MTT assay) over HL60 cells compared to 
those obtained for the salannin-type limonoid 3-O-deacetyl-4’-demethyl-28-
oxosalaninin (IC50 = 2.8 µM by MTT assay). Takeya et al. evaluated some azadirachtin- 
and trichilin-type limonoids against P388 lymphocytic leukemia cells, and the latter 
showed the lowest inhibitory values (Takeya et al., 1996a; 1996b). This improved 
cytotoxic activity observed for trichilin-type limonoids may be related to some 
characteristic structural features that merit further consideration. Most trichilin-type 
limonoids contain both a C-19/28 oxygen bridge and a C14/15-epoxide ring, which 
were found to be involved in cell growth inhibition (Tan and Luo, 2011). The 
comparison of the IC50 values of 12-hydroxyamoorastatin (0.004 µM) and the C14/15 
epoxy lacking amoorastatone (58 µM), both compounds isolated from Aphanamixis 
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grandifolia (Meliaceae), against P388 lymphocytic leukemia cells suggest that this 
group is required for improved cytotoxic activity (Polonsky et al., 1979). Similarly, 
toosendanin isolated from Melia toosendan (Meliaceae), which also contains the C14/15 
epoxide, resulted highly cytotoxic against KB cells, whereas toosendanal, obtained from 
the same tree and possessing a C-15 keto structure, was not toxic to the same cells 
(Tada et al., 1999).  
 In the light of our findings and considering the key role of p53 in the integration 
of signals from diverse pathways that regulate the cell cycle and apoptosis (Finlan and 
Hupp, 2005; Maddika et al., 2007), we evaluated whether the biological effects 
mediated by 1 were related to the induction and activity of p53 and its downstream 
target p21. The increased expression profile of these proteins was similar to treatment 
with HU but not with DOX (Fig. 7A). This is consistent with previous findings, 
showing that HU induced an arrest in S-phase, where the induction of p53 and p21 is 
known to be subtle (Gottifredi et al., 2001a). In contrast, treatment with DOX triggered 
a stronger induction of p53 and p21 (Fig. 7A), which correlates with a robust cell cycle 
arrest in G2 (Fig. 2A). 
It was found that p53-dependent apoptosis was responsible for the cytotoxicity 
observed in HCT116 after treatment with 1 (Fig. 7A and B). The fact that p53, but not 
p21, was linked to the cytotoxic effect mediated by 1 strongly suggests that only the 
pro-apoptotic functions of p53 are critical for this effect. In fact, while it is well-
established that the p53/p21 axis promotes cell cycle arrest in G1 and G2, p21 is 
actively maintained at low levels by transcriptional and proteolytic mechanisms during 
the S-phase (Soria and Gottifredi, 2010). This might explain the attenuated 
accumulation of p21 induced by 1 in comparison to DOX (Fig 7A). Moreover, an 
analogous interpretation could be drawn in relation to the similar sensitivity observed in 
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p21-/- cells versus parental HCT116 cells (Fig 7B), because both cell lines share a wt 
p53 status. The requirement of a normal expression of p53 to trigger an efficient 
execution of the death program (Lowe et al., 1993) could explain, at least in part, the 
different results obtained in inhibitory values between the colorectal carcinoma cells 
HCT116 and both leukemia cell lines, CCRF-CEM and K562.  
As previously stated, although compound 1 was considered effective for 
inhibiting both leukemic cell lines (IC50 = 1.4 and 4.6 µM, for CCRF-CEM and K562, 
respectively), it proved remarkably more effective for inducing death over the HCT116 
cells (IC50 = 0.2 µM). Beyond the different genetic backgrounds among these cell lines, 
it is important to highlight that both leukemia-derived cell lines are p53-mutated, in 
contrast to HCT116. Briefly, sequencing of the p53 gene in the K562 cell line 
demonstrated a mutation in exon 5, characterized by a single base insertion (cytosine) 
between codons 135 and 136 (Law et al., 1993). This frameshift mutation leads to an N-
terminal truncated protein of 147 amino acids. Only the mutated sequence was present, 
suggesting that the normal allele has been lost. On the other hand, CCRF-CEM cells are 
also p53-mutated in codons 524 and 743, but these cells are heterozygous for this 
mutation (Geley et al., 1997). This heterozygosity of CCRF-CEM cells could explain 
their higher sensitivity to 1 (IC50 = 1.4 µM) than to K562 (IC50 = 4.6 µM). A similar 
approach could be applied to explain the results found in studies performed with other 
cell lines exposed to 12-hydroxyamoorastatin. Comparing the IC50 values obtained for 
the tumor cell lines SK-OV-3, HCT-15, A549; XF-498 and SK-MEL-2 (Ahn et al., 
1994) with their p53 status, a possible explanation could be drawn. From the IC50 values 
reported by Ahn et al. (Ahn et al., 1994), the SK-OV-3 was the least sensitive to the 
treatment. This cell line carries a homozygous mutation for p53 (C.267delC), while the 
most affected cell lines are heterozygous (HCT-15 and SK-MEL-2) or wild-type (A549 
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and XF-498). It is worth mentioning that, despite A549 cells being p53 wt, this cell line 
was not the most affected. This could be explained by the fact that these cells are 
characterized by a stable over-expression of the Nrf2 transcription factor, which is 
involved in the promotion of a cellular protective response against different toxic 
aggressions (Wang et al., 2008). Indeed, these cells have shown enhanced resistance to 
a broad spectrum of chemotherapeutic agents, including cisplatin, DOX and etoposide 
(Wang et al., 2008). This is in accordance with the lower sensitivity that these cells 
showed when treated with DOX or compound 1 in our experiments.  
Taken together, the results described in this work position compound 1 as a 
strong antitumoral agent, with great potential for targeting p53+ tumors. The present 
investigation is the first effort toward a comprehensive understanding of the 
mechanisms underlying the anticancer activity of compound 1. This information is of 
great value for positioning 1 as a promising antitumor agent that may be used to 
improve anticancer therapy.   
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Legends for figures 
 
 
Fig. 1. Chemical structures of the constituents of the isomeric mixture of 
tetranortriterpenoids (1) meliartenin (A) and 12-hydroxyamoorastatin (B). 
 
Fig. 2. Treatment with 1 triggered S-phase accumulation A) HCT116 cells were plated 
in 12-well plates and, 24 h later, the cells were treated with 1 at 0.2, 0.4 and 0.8 µM, 1% 
acetonitrile (control), doxorubicin (DOX) 0.6 µM or hydroxyurea (HU) 2 mM. After a 
24, 48 and 72 h incubation period, cells were fixed and stained with propidium iodide 
(PI). DNA content was analyzed by flow cytometry. Histograms are representative of 
three independent experiments. B) The cell cycle profiles obtained in A) were analyzed 
using Flowjo and the percentage of cells at each phase of the cell cycle was quantified. 
Data are presented as mean ± SE of three independent experiments. Differences with 
respect to control were analyzed using two-way analysis of variance (ANOVA) (*** p 
< 0.001, ** p < 0.01).  
 
Fig. 3. S-phase progression is permanently blocked after treatment with 1 A) HCT116 
cells were treated with 1 at 0.2, 0.4 and 0.8 µM and HU for 24, 48 and 72 h. After 
exposure, cells were pulsed for 20 min with BrdU and immediately fixed with 70% ice-
cold ethanol at 4°C. Subsequently, cells were stained with propidium iodide (PI) and 
processed for BrdU detection, using a specific antibody followed by a secondary 
antibody conjugated to FITC. Dual channel flow cytometry was performed to determine 
the DNA content and BrdU simultaneously. A representative plot of three independent 
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experiments at 0.2 µM is shown. B) The percentage of BrdU+ vs BrdU- cells within the 
S-phase at different time points was calculated using Flowjo.  
 
Fig. 4. Treatment with 1 triggered cell death in a time-dependent manner A) HCT116 
cells were plated in 12-well plates and 24 h later were treated with 1 at 0.2, 0.4 and 0.8 
µM, 1% acetonitrile (control), doxorubicin (DOX) 0.6 µM or hydroxyurea (HU), 2 mM 
for a period of 24, 48 and 72 h. After treatment, cells were collected and stained with 
SYTOX Red dead cell stain and analyzed by flow cytometry. Viable cells (Sytox Red-) 
can be distinguished from dead cells (SYTOX Red+). Data are represented as the mean 
± SE of three independent experiments. Histograms are representative of three 
independent experiments. B) Representative profile of SYTOX Red dead cell stain at 72 
h post treatment with 1, HU and DOX.  
 
Fig. 5. Treatment with 1 triggers apoptosis. HCT116 cells were plated in 12-well plates 
and 24 h later were treated with 1 at 0.2 µM, 1% acetonitrile (control), or hydroxyurea 
(HU) 2 mM for a period of 24, 48 and 72 h. After treatment, cells were suspended in 
Annexin-binding buffer and stained with Annexin V-FITC conjugate and 5 nM SYTOX 
Red dead cell stain followed by dual channel flow cytometric analysis. Four sub-
populations are identified: Q4: viable (Annexin V- / Sytox Red-), Q3: early apoptotic 
(Annexin V+ / Sytox Red -), Q2: late apoptotic (Annexin V+ / Sytox Red +) and Q1: 
necrotic (Annexin V- / Sytox Red+). Quantification of the percentage of cells in each 
quadrant is shown. A representative plot of three independent experiments is shown. 
 
Fig. 6. Treatment with 1 decreased the clonogenic potential. A) HCT116 cells were 
plated in 96-well plates and 24 h later were treated with 1 at different doses. After 72 h, 
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cells were plated in 6-well plates containing drug-free media at different densities 
ranging from 80-2560 cells per well. After 10 days incubation, colonies were washed 
with PBS, fixed and stained with crystal violet. Colonies were counted and percentage 
the surviving fraction was plotted. (B) An image of one representative experiment is 
shown. The number of cells in each well is indicated. 
 
Fig. 7. P53 tumor suppressor was required for the cytotoxic effect induced by 1. A) 
HCT116 cells were treated with 1 at 0.2, 0.4 and 0.8 µM, 1% acetonitrile (control); 
doxorubicin (DOX) 0.6 µM or hydroxyurea (HU) 2 mM. At 24 and 48 h, samples were 
collected and processed by Western Blot using specific p53 and p21 antibodies. Actin 
was used as a loading control. Results are from a single experiment, representative of 
three independent experiments. B) A co-culture of isogenic HCT116 cells (wild-type, 
p53-/- and p21-/-) tagged with different fluorescent proteins was treated with different 
doses of 1. At 6 days, samples were collected and the proportion of each cell population 
was determined by dual channel flow cytometry. P53 wt (Mcherry+ / iRFP -); p21-/- 
(Mcherry - / iRFP +) and p53-/- ( Mcherry - / iRFP -). Data analysis and quantifications 
for each protein, correcting for loading, was performed using Image Studio software. 
Quantification of the percentage of cells of each population is shown. For interpretation 
of the references to color in this figure legend, the reader is referred to the web version 
of this article. 
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Table 1 
 Anti-proliferative effect of 1 on a panel of tumor-derived cells (µM) 
 
 
Compounds 
IC50 (µM) values and 95% confidence limits (lower, upper) 
CCRF-CEM K562 A549 HCT116 
1 1.43 (0.66-
3.08) 
4.64 (1.63-
13.23) 
4.27 (0.39-
46.64) 
0.20 (0.09-
0.49) 
DOX 0.13 (0.06-
0.30) 
1.15 (0.52-
2.59) 
5.12 (1.02-
25.7) 
0.60 (0.26-
1.41) 
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